Immutep (NASDAQ:IMMP) Share Price Crosses Above Fifty Day Moving Average of $2.72

Immutep Limited (NASDAQ:IMMPGet Free Report) crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $2.72 and traded as high as $2.86. Immutep shares last traded at $2.85, with a volume of 385,147 shares.

Wall Street Analysts Forecast Growth

Separately, Capital One Financial started coverage on Immutep in a research note on Friday, May 17th. They issued an “overweight” rating and a $10.00 price target on the stock.

View Our Latest Research Report on Immutep

Immutep Stock Up 8.8 %

The firm’s 50 day simple moving average is $2.72 and its two-hundred day simple moving average is $2.44.

Institutional Trading of Immutep

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. PFG Investments LLC bought a new position in Immutep in the first quarter worth approximately $119,000. Oracle Investment Management Inc. lifted its holdings in shares of Immutep by 9.4% in the 1st quarter. Oracle Investment Management Inc. now owns 564,879 shares of the biotechnology company’s stock worth $1,316,000 after purchasing an additional 48,449 shares in the last quarter. Virtu Financial LLC grew its position in Immutep by 269.4% in the 1st quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 32,864 shares during the period. Meridian Wealth Management LLC increased its stake in Immutep by 3.6% during the 4th quarter. Meridian Wealth Management LLC now owns 322,450 shares of the biotechnology company’s stock valued at $774,000 after purchasing an additional 11,250 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in Immutep by 15.4% during the first quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company’s stock worth $82,000 after buying an additional 4,700 shares during the last quarter. 2.32% of the stock is owned by institutional investors.

Immutep Company Profile

(Get Free Report)

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.

Featured Stories

Receive News & Ratings for Immutep Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immutep and related companies with MarketBeat.com's FREE daily email newsletter.